Innoviva

INVA · NASDAQ

$21.28+$0.20 (+0.95%)TodayMarket closed · Oct 20, 5:21 PM ET

Prev close $21.08

Latest news

Press releaseOct 19, 8:00 AM ETBusiness Wire
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Press releaseSep 2, 8:00 AM ETBusiness Wire
Innoviva to Participate in Upcoming Investor Conferences
Press releaseAug 11, 4:05 PM ETBusiness Wire
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
NewsAug 5, 4:43 PM ET
Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate
Press releaseAug 5, 4:05 PM ETBusiness Wire
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Press releaseJun 18, 8:00 AM ETBusiness Wire
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Press releaseJun 16, 8:00 AM ETBusiness Wire
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
Press releaseJun 1, 11:00 AM ETBusiness Wire
Innoviva to Participate in Upcoming Investor Conferences
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
NewsMay 6, 4:40 PM ET
Innoviva Q1 EPS $2.22 Beats $0.36 Estimate, Sales $97.994M Miss $101.555M Estimate
Press releaseMay 6, 4:05 PM ETBusiness Wire
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
NewsFeb 25, 6:38 PM ET
Innoviva Q4 EPS $1.94 Beats $0.66 Estimate, Sales $114.613M Beat $101.530M Estimate
Press releaseFeb 19, 8:00 AM ETBusiness Wire
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Press releaseDec 12, 4:56 PM ETBusiness Wire
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
NewsDec 12, 1:27 PM ET
The FDA Today Approved Nuzolvence (Zoliflodacin) Granules That Dissolve In Water; Medicine Can Treat Uncomplicated Urogenital Gonorrhea In Adults And Children 12 Years And Older
Press releaseDec 11, 6:35 PM ETBusiness Wire
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Press releaseNov 25, 7:00 AM ETBusiness Wire
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
NewsNov 5, 4:47 PM ET
Innoviva Q3 EPS $1.08 Beats $0.52 Estimate, Sales $107.800M Beat $91.309M Estimate
Press releaseNov 5, 4:05 PM ETBusiness Wire
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
Press releaseOct 21, 8:00 AM ETPRNewswire
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
Press releaseOct 20, 8:00 AM ETBusiness Wire
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
Press releaseOct 7, 8:00 AM ETBusiness Wire
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
NewsSep 30, 4:01 PM ET
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock
Press releaseAug 26, 7:00 AM ETBusiness Wire
Innoviva to Participate in Upcoming Investor Conferences
Press releaseAug 13, 8:00 AM ETBusiness Wire
Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
NewsAug 11, 2:01 PM ET
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
NewsAug 6, 5:12 PM ET
Innoviva Q2 EPS $0.77 Beats $0.49 Estimate, Sales $100.283M Beat $87.130M Estimate
Press releaseAug 6, 4:05 PM ETBusiness Wire
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
Press releaseJun 12, 7:00 AM ETBusiness Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Press releaseJun 10, 6:00 AM ETBusiness Wire
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Press releaseJun 3, 7:00 AM ETBusiness Wire
Innoviva to Participate in Upcoming Investor Conferences
Press releaseMay 20, 6:00 AM ETBusiness Wire
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
NewsMay 7, 4:52 PM ET
Innoviva Q1 EPS $(0.74) Misses $0.38 Estimate, Sales $88.63M Beat $82.67M Estimate
Press releaseMay 7, 4:05 PM ETBusiness Wire
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
NewsApr 1, 7:56 AM ETAvi Kapoor
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseMar 12, 5:08 PM ETPRNewswire
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva to Participate in Upcoming Investor Conferences

Earnings Scheduled For May 6, 2026

Innoviva Q1 EPS $2.22 Beats $0.36 Estimate, Sales $97.994M Miss $101.555M Estimate

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Q4 EPS $1.94 Beats $0.66 Estimate, Sales $114.613M Beat $101.530M Estimate

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

The FDA Today Approved Nuzolvence (Zoliflodacin) Granules That Dissolve In Water; Medicine Can Treat Uncomplicated Urogenital Gonorrhea In Adults And Children 12 Years And Older

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Innoviva Q3 EPS $1.08 Beats $0.52 Estimate, Sales $107.800M Beat $91.309M Estimate

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Beyond The Numbers: 5 Analysts Discuss Innoviva Stock

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Expert Outlook: Innoviva Through The Eyes Of 4 Analysts

Innoviva Q2 EPS $0.77 Beats $0.49 Estimate, Sales $100.283M Beat $87.130M Estimate

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Innoviva to Participate in Upcoming Investor Conferences

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Innoviva Q1 EPS $(0.74) Misses $0.38 Estimate, Sales $88.63M Beat $82.67M Estimate

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva